Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Fellowship - Priority Announcement: Gastroenterology

Ontario Institute for Cancer Research (Toronto, Ontario)

$39,375.00

Development of a genomic signature to identify progression of Barrett's Esophagus to Esophageal Adenocarcinoma

EF 2013-14

Résumé
Approximately 3 million Canadians have chronic acid reflux disease, and of those, roughly 800 thousand have Barrett's Esophagus (BE). BE is a change in the surface of the esophageal lining caused by regurgitation of stomach contents into the esophagus. BE that is the single most important risk factor for development of esophageal cancer. Diagnosis and monitoring of BE is currently done by endoscopy, which is a time consuming and uncomfortable procedure. Consequently only 1 in 20 patients participate in regular screening. Endoscopy requires highly trained medical professionals, specialized equipment, and is not a risk free procedure. In Canada alone, esophageal cancer affects approximately 1,500 new patients annually; most of which are identified at late stages and when treatment options are limited. If detected early, treatment of EAC is usually possible by removal of the cancerous area, leaving a normal esophageal lining after surgery. This project is developing a genetic test that will be able to replace regular endoscopies with a quick procedure that is easily performed in a family doctor's office. This technology will be able to identify patients progressing to cancer at early stages of the disease without endoscopy. We expect that the combination of this genetic test and the avoidance of regular endoscopies will increase the rate of BE patients enrolled in regular screening programs, enabling health care providers to identify and treat people who would otherwise succumb to esophageal cancer.
Programme
Fellowship - Priority Announcement: Gastroenterology
Emplacement
Ontario, Canada
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
302102
Name
Krzyzanowski Paul M
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Partnername
Canadian Association of Gastroenterology (Oakville, Ontario); PENTAX Medical Company (Montvale, NJ)
Instname2
Cancer Research
Theme2
Health systems / services
Prcname2
Fellowships - Post-PhD
Projecttitle
Development of a genomic signature to identify progression of Barrett's Esophagus to Esophageal Adenocarcinoma
Programtype2
Fellowship Programs
Orgnameinp2
Ontario Institute for Cancer Research (Toronto, Ontario)
Cihramount2
$39,375
Cihrequipment2
$0
Programname2
Fellowship - Priority Announcement: Gastroenterology
Keyworddelim
Barrett'S Esophagus; Cancer Precursors; Esophageal Adenocarcinoma; Genomics; Next-Generation Sequencing; Oncogenic Pathways; Progression Signatures; Signalling Pathways; Systems Biology
Abstract
Approximately 3 million Canadians have chronic acid reflux disease, and of those, roughly 800 thousand have Barrett's Esophagus (BE). BE is a change in the surface of the esophageal lining caused by regurgitation of stomach contents into the esophagus. BE that is the single most important risk factor for development of esophageal cancer. Diagnosis and monitoring of BE is currently done by endoscopy, which is a time consuming and uncomfortable procedure. Consequently only 1 in 20 patients participate in regular screening. Endoscopy requires highly trained medical professionals, specialized equipment, and is not a risk free procedure. In Canada alone, esophageal cancer affects approximately 1,500 new patients annually; most of which are identified at late stages and when treatment options are limited. If detected early, treatment of EAC is usually possible by removal of the cancerous area, leaving a normal esophageal lining after surgery. This project is developing a genetic test that will be able to replace regular endoscopies with a quick procedure that is easily performed in a family doctor's office. This technology will be able to identify patients progressing to cancer at early stages of the disease without endoscopy. We expect that the combination of this genetic test and the avoidance of regular endoscopies will increase the rate of BE patients enrolled in regular screening programs, enabling health care providers to identify and treat people who would otherwise succumb to esophageal cancer.
Competitiondate
201311
Approvedterm2
1 yr 9 mths
Pinamesdelim
Krzyzanowski, Paul M
Approvedterm
1 an 9 mois
Cihrcontribution2
Inst of Nutr Metabolism &Diab~ $39,375~ $0~